Quick Answer
Sonoma Pharmaceuticals, Inc. reported Operating Income Loss of -$3.71 million for the year ending 2025.
- Sonoma Pharmaceuticals, Inc. showed an increase of +21.1% in Operating Income Loss from 2024 to 2025.
- This data is from Sonoma Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on June 17, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2012: -$680.0 thousand | Q2 2013: -$1.13 million | Q3 2013: -$1.27 million | Q4 2013: -$1.55 million | Q2 2014: -$1.51 million | Q3 2014: -$1.54 million | Q4 2014: -$1.95 million | Q2 2015: -$2.31 million | Q3 2015: -$1.86 million | Q4 2015: -$4.19 million | Q2 2016: -$3.51 million | Q3 2016: -$2.99 million | Q4 2016: -$3.57 million | Q2 2017: -$3.38 million | Q3 2017: -$2.86 million | Q4 2017: -$3.20 million | Q2 2018: -$3.55 million | Q3 2018: -$2.65 million | Q4 2018: -$2.35 million | Q2 2019: -$1.91 million | Q3 2019: -$1.29 million | Q4 2019: -$1.11 million | Q2 2020: -$665.0 thousand | Q3 2020: $169.0 thousand | Q4 2020: -$138.0 thousand | Q2 2021: -$904.0 thousand | Q3 2021: -$964.0 thousand | Q4 2021: -$958.0 thousand | Q2 2022: -$855.0 thousand | Q3 2022: -$731.0 thousand | Q4 2022: -$1.83 million | Q2 2023: -$1.24 million | Q3 2023: -$1.21 million | Q4 2023: -$844.0 thousand | Q2 2024: -$1.17 million | Q3 2024: -$850.0 thousand | Q4 2024: -$1.03 million | Q2 2025: -$1.10 million | Q3 2025: -$337.0 thousand | Q4 2025: -$678.0 thousand.
- Over the full 15 years of available data (2011 to 2025), Sonoma Pharmaceuticals, Inc.'s Operating Income Loss has grown by 50.6%.
- Historical annual values: Fiscal year 2025: -$3.71 million | Fiscal year 2024: -$4.70 million | Fiscal year 2023: -$4.57 million | Fiscal year 2022: -$5.89 million | Fiscal year 2021: -$3.45 million | Fiscal year 2020: -$7.39 million | Fiscal year 2019: -$11.26 million | Fiscal year 2018: -$14.19 million | Fiscal year 2017: -$12.97 million | Fiscal year 2016: -$14.71 million | Fiscal year 2015: -$6.66 million | Fiscal year 2014: -$6.05 million | Fiscal year 2013: -$3.37 million | Fiscal year 2012: -$6.47 million | Fiscal year 2011: -$7.51 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: